Principia BioPharma

Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, has created a revolutionary new way to design and develop oral small molecule therapies that are more potent, selective, durable and safer than currently available drugs. The Company has utilized its proprietary Tailored Covalency® technology to develop a portfolio of drug candidates that exhibit antibody-like specificity to benefit patients with autoimmune and inflammatory diseases and cancer. Its most advanced drug candidate, PRN1008, a reversible covalent BTK inhibitor, is in Phase 2 development for pemphigus vulgaris, an orphan autoimmune disease and PRN1371 is in Phase 1 for solid tumors. Since Principia began operations in 2011, its highly productive approach has led to the rapid advancement of PRN1008 and PRN1371 into the clinic and the creation of a growing portfolio of programs for autoimmune and inflammatory diseases.

TypeSubsidiary
Parent CompanySanofi
HQSouth San Francisco, CA, US
Founded2008
Websiteprincipiabio.com
Cybersecurity ratingAMore
Principia BioPharma was founded in 2008 and is headquartered in South San Francisco, CA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Principia BioPharma

David Goldstein

David Goldstein

Site Head and Chief Scientific Officer
Betsy Santos

Betsy Santos

Senior Vice President, People
Show more

Principia BioPharma Office Locations

Principia BioPharma has an office in South San Francisco
South San Francisco, CA, US (HQ)
220 E Grand Ave
Show all (1)

Principia BioPharma Financials and Metrics

Summary Metrics

Founding Date

2008

Total Funding

$89.9 m

Investors

In total, Principia BioPharma had raised $89.9 m. Principia BioPharma is a subsidiary of Sanofi

Principia BioPharma Revenue

Principia BioPharma's revenue was reported to be $35.16 m in FY, 2019
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

5.2m69.1m35.2m

General and administrative expense

4.8m6.4m11.5m19.8m

R&D expense

22.3m25.4m40.5m74.1m

Operating expense total

27.1m31.8m52.0m93.9m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.5m18.6m5.2m30.0m50.0m

General and administrative expense

1.3m2.9m4.5m5.2m5.0m7.4m9.2m

R&D expense

6.1m9.2m15.5m18.7m18.4m26.7m30.9m

Operating expense total

7.4m12.1m20.0m24.0m23.3m34.1m40.1m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.9m41.1m34.5m39.5m

Prepaid Expenses

934.0k1.8m3.8m4.2m

Current Assets

6.9m42.9m180.8m319.7m

PP&E

296.0k209.0k1.7m9.7m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

9.8m149.1m14.7m41.1m29.4m59.4m170.5m

Prepaid Expenses

1.4m2.5m3.3m2.2m1.7m4.6m52.9m

Current Assets

29.9m190.9m166.9m171.7m152.4m316.1m369.4m

PP&E

470.0k552.0k10.7m10.6m10.2m9.4m9.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(30.6m)(28.7m)18.2m(53.8m)

Depreciation and Amortization

232.0k178.0k252.0k1.8m

Accounts Payable

696.0k1.3m1.0m(2.1m)

Cash From Operating Activities

(24.8m)26.8m(21.2m)(42.5m)
Quarterly
USDQ2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(18.7m)(25.9m)2.1m8.8m(13.7m)(6.6m)(28.9m)(21.7m)

Depreciation and Amortization

93.0k138.0k107.0k176.0k346.0k835.0k1.3m502.0k1.0m

Accounts Payable

224.0k(1.3m)(160.0k)1.3m(35.0k)(52.0k)(1.6m)(227.0k)(610.0k)

Cash From Operating Activities

964.0k(6.4m)(22.3m)(15.9m)(16.4m)(2.5m)(20.9m)(27.5m)(54.4m)
USDFY, 2016

Financial Leverage

-0.6 x
Show all financial metrics

Principia BioPharma Operating Metrics

Apr, 2018

Phase II Patients Enrolled

27
Show all operating metrics

Principia BioPharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Principia BioPharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Principia BioPharma Online and Social Media Presence

Embed Graph

Principia BioPharma Company Culture

  • Overall Culture

    D

    60/100

  • CEO Rating

    D-

    60/100

  • Compensation

    D-

    50/100

Learn more on Comparably

Principia BioPharma News and Updates

Sanofi completes Principia Biopharma Inc. acquisition

Sanofi completes Principia Biopharma Inc. acquisition

Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.

                                                                                                                                                            

SHAREHOLDER ALERT: WeissLaw LLP Investigates Principia Biopharma Inc.

NEW YORK, Aug. 17, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Principia Biopharma Inc. ("PRNB" or the "Company") (NASDAQ: PRNB) in connection with the proposed acquisition of the Company...

Thinking about buying stock in Comstock Mining, Sorrento Therapeutics, TRACON Pharmaceuticals, Principia Biopharma, or Norwegian Cruise Line?

NEW YORK, Aug. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LODE, SRNE, TCON, PRNB, and NCLH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Sanofi to acquire Principia Biopharma

Sanofi to acquire Principia Biopharma 
Show more

Principia BioPharma Blogs

Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease

Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease Content Import Thu, 09/17/2020 - 08:03 Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease September 17, 2020 Thi…

Principia Biopharma Reports Second Quarter 2020 Financial Results

Principia Biopharma Reports Second Quarter 2020 Financial Results Content Import Thu, 08/06/2020 - 16:09 Principia Biopharma Reports Second Quarter 2020 Financial Results August 6, 2020 This release is a backfill from a News Wire Earnings …

Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus

Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus Content Import Fri, 06/12/2020 - 16:05 Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus June 12, 2020 This release is a backfill from a News Wire …

Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial Content Import Fri, 06/12/2020 - 06:05 Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial June 12, 2…

Principia Biopharma to Hold Virtual Analyst Event to Discuss BTK Inhibition: Beyond B Cells and Antibodies

Event scheduled for 4:00 pm ET on Tuesday, June 16th SOUTH SAN FRANCISCO, Calif. , June 03, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced that it will host a

Principia Announces Data Presentations of Rilzabrutinib in Patients with Immune Thrombocytopenia (ITP) at Two Upcoming Virtual Medical Meetings

SOUTH SAN FRANCISCO, Calif. , May 26, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced upcoming presentations at the European Hematology Association (EHA) and the
Show more

Principia BioPharma Frequently Asked Questions

  • When was Principia BioPharma founded?

    Principia BioPharma was founded in 2008.

  • Who are Principia BioPharma key executives?

    Principia BioPharma's key executives are David Goldstein and Betsy Santos.

  • How many employees does Principia BioPharma have?

    Principia BioPharma has 86 employees.

  • What is Principia BioPharma revenue?

    Latest Principia BioPharma annual revenue is $35.2 m.

  • What is Principia BioPharma revenue per employee?

    Latest Principia BioPharma revenue per employee is $408.8 k.

  • Who are Principia BioPharma competitors?

    Competitors of Principia BioPharma include Rani Therapeutics, Libbs Farmaceutica and Servier.

  • Where is Principia BioPharma headquarters?

    Principia BioPharma headquarters is located at 220 E Grand Ave, South San Francisco.

  • Where are Principia BioPharma offices?

    Principia BioPharma has an office in South San Francisco.

  • How many offices does Principia BioPharma have?

    Principia BioPharma has 1 office.